Monaghan Medical yesterday touted data from a 6-month retrospective study showing that its Aerobika device reduced drug use for treatment of chronic obstructive pulmonary device.
The Syracuse, N.Y.-based company says its oscillating positive expiratory pressure therapy device is designed to expand the airways, help expel mucus to the upper airways and aid in drug deposition.
The study included 810 COPD patients with chronic bronchitis. Half of the participants received treatment using the Aerobika device and the other half used propensity score-matched controls. Researchers hoped to evaluate if the Aerobika device could reduce moderate and severe exacerbations of COPD.
The study showed that for patients treated with Aerobika, antibiotics were used 57% less and oral corticosteroids were used 89% less than those treated without the device. Researchers also found that patients who used Aerobika exhibited lower costs throughout the study period, with an average reduction of $6,347 per patient at 30 days and almost $10,000 per patient at 6 months for all in-patient and out-patient costs.
They study demonstrated that using the device resulted in a 28% reduction in exacerbations in just 30 days of treatment, when used alongside usual COPD medications.
“One of our major goals in developing the Aerobika device was to safely improve patient outcomes,” VP clinical strategy & development Dominic Coppolo said in prepared remarks. “These real-world findings are encouraging as we continue to conduct additional studies to further demonstrate the impact of our device in this high risk patient population.”
